SkQ1 Plastoquinone.
SkQ1 Plastoquinone supplementation for targeted health support. Delivers antioxidant protection directly to mitochondrial membranes, the site where most cellular oxidative damage occurs. In theory, this could slow aging at its source.
Reviewed March 2026
- Category
- Antioxidant
What SkQ1 Plastoquinone is, and what it does.
- Does it work
- Scientifically fascinating with impressive animal data. But as an oral supplement for humans? We're still in the educated-guess phase.
- How much to take
- No established human dose for oral supplementation. Eye drops use nanomolar concentrations. Oral products typically contain 50-200mcg.
- Time to feel it
- There is no measured human timeline for an oral dose. Animal and eye-drop work reports changes across weeks to months, and nothing subjective has been recorded for capsules.
- The first dose
- A dose is a tiny amount in oil with no sensation attached. The molecule concentrates inside mitochondria within hours by charge alone, and no same-day human change has been measured.
- With regular use
- Theoretical mitochondrial protection. Animal studies show lifespan extension in some models. No human longevity data.
- How well tolerated
- Eye drop form is well-tolerated. Oral supplementation safety profile is largely unknown in humans.
- How it feels
- Nothing you'll perceive directly. This is about cellular health, not acute effects.
- The overlooked benefit
- Uptake depends on mitochondrial membrane charge, so it gathers most in the mitochondria still holding a strong potential and least in the ones that have lost it.
50 to 250mcg a day is where SkQ1 Plastoquinone works.
Source: Skulachev et al., Biochim Biophys Acta, 2009; mitochondria-targeted antioxidant research
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
SkQ1 Plastoquinone has emerging evidence. Based on 15+ studies.
- Extends lifespan in animalsMultiple species studies
- Treats dry eye diseaseRussian clinical trials
- Slows human agingNo direct human evidence yet
Questions people ask about SkQ1 Plastoquinone.
- What makes it different from CoQ10?
- SkQ1 is engineered to accumulate in mitochondria 1000x more effectively than natural antioxidants. It's targeted therapy vs. shotgun approach.
- Is it approved anywhere?
- Yes. Visomitin eye drops are approved in Russia for dry eye and other eye conditions.
- Does it extend lifespan?
- In some animal models, yes. Median lifespan extension of 15-20% in several species. Humans? No data yet.
- How do I take it?
- Eye drops for eye health. Oral supplements exist but are unregulated and experimental.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Both attach a redox-active quinone to a triphenylphosphonium cation so it accumulates across the mitochondrial membrane potential. Stacking two of them adds the same lipophilic cation load to the same membrane rather than adding a new mechanism.
CoQ10 is the native mitochondrial quinone carrier and SkQ1 is a plastoquinone head group steered into the same membrane. Both cycle between quinone and quinol, with CoQ10 also serving the electron transport chain that SkQ1 does not join.
SkQ1 is plastoquinone with a decyl linker and a cationic tail added to direct it into mitochondria. The antioxidant chemistry is the plastoquinone head group in both cases.
Tocopherol stops lipid peroxidation chains throughout cell membranes while the targeted quinol concentrates that same hydrogen-donating chemistry inside mitochondria. The two cover different membrane compartments.
A quinone antioxidant only keeps working while it is returned to its reduced quinol form. Dihydrolipoate feeds the cellular reducing pool that performs that step.
NR raises the NAD pool that drives mitochondrial dehydrogenases, while a targeted quinone limits lipid peroxidation in the same membranes. The two act on supply and on protection respectively.
A quinone antioxidant only keeps working if something returns it to its reduced quinol state, and the cell does that through NADPH-dependent flavoenzymes. Glutathione reductase and thioredoxin reductase both require FAD, made from riboflavin. Riboflavin status therefore sits underneath any redox-cycling compound rather than beside it.
The mitochondrial peroxide-handling enzymes glutathione peroxidase 4 and thioredoxin reductase 2 both carry a selenocysteine at the active site. They clear the lipid peroxides that a membrane-targeted antioxidant is aimed at. Without adequate selenium that clearance step is limited whatever else is present.
The mitochondrial glutathione pool is the main reducing currency for peroxide removal in that compartment and participates in returning oxidised species to their reduced state. A quinol acting in the inner membrane and glutathione acting in the matrix cover different phases of the same compartment. Oral glutathione absorption is itself contested, which is why this stays promising.
Cysteine availability sets the ceiling on how much glutathione a cell can make, and NAC supplies it. Keeping the matrix glutathione pool stocked supports the enzymatic step that regenerates oxidised antioxidants. This is upstream substrate support, not a direct interaction with the quinone.
Ascorbate reduces radicals at the membrane and water interface, including the tocopheroxyl radical formed when vitamin E does its job. Quinols in the membrane participate in the same recycling network. Worth noting that ascorbate can also reduce quinones to semiquinones under some conditions, which is a pro-oxidant direction rather than an antioxidant one.
Astaxanthin spans the lipid bilayer with polar ends at both surfaces, which places it differently from a quinone sitting in the hydrophobic core. Covering different depths of the same membrane is the argument for pairing. There is no combination measurement, so this stays early.
PQQ is itself a redox-cycling quinone and has been described as influencing PGC-1 alpha signalling associated with mitochondrial biogenesis. Two quinones with different targeting chemistry may act on different aspects of the same organelle. Combining redox-active quinones also raises the possibility of additive pro-oxidant behaviour at higher concentrations, which is worth stating alongside the rationale.
Ubiquinol and a plastoquinone derivative occupy overlapping territory in the inner membrane and both take part in electron handling there. That overlap can mean redundancy as easily as it means addition, since both compete for the same membrane environment and the same reducing equivalents. State it as an interaction to understand rather than a stack to assume.
Regenerating oxidised antioxidants in mitochondria draws on NADPH, which is supplied in part from the NAD pool through nicotinamide nucleotide transhydrogenase. A low pyridine nucleotide pool limits how many cycles an antioxidant can run. The link is real biochemistry; the supplement-level effect is not established.
Nicotinamide mononucleotide feeds NAD synthesis through the salvage pathway, and NAD status underpins mitochondrial reducing capacity. A membrane-targeted antioxidant depends on that capacity to keep cycling. No combination has been measured, so this is mechanism only.
Carnitine moves long-chain fatty acids into the matrix for beta-oxidation, which is substrate supply rather than redox protection. The two act on different aspects of the same organelle. Formulas built around mitochondrial function commonly carry both, without a combination measurement behind it.
Taurine is incorporated into mitochondrial tRNA wobble bases, which affects how accurately the organelle translates its own respiratory chain subunits. That is a synthesis-side contribution rather than a redox one. Adjacent mechanism, no measured pairing.
Redox-cycling quinones can reduce ferric iron to ferrous, which then drives hydroxyl radical formation from peroxide. That turns an antioxidant into a source of oxidative damage under the wrong conditions. The concentration dependence of quinone antioxidants, protective at low levels and pro-oxidant at higher ones, is the reason this flag belongs on the row.
Lutein concentrates in the retina and lens where it absorbs short-wavelength light and quenches singlet oxygen. That is a different protective chemistry in the same tissue that ophthalmic quinone preparations are applied to. Adjacent rather than interacting, and no combination has been measured.
Hyaluronic acid raises the viscosity of an eye drop and lengthens how long it stays on the ocular surface, which is a delivery effect rather than a pharmacological one. Any topical active benefits from longer contact. This is formulation practice and carries no claim about the active itself.
A triphenylphosphonium conjugate is lipophilic and depends on lipid solubilisation for oral uptake. A medium-chain triglyceride vehicle keeps it dispersed through digestion. This addresses getting the molecule absorbed, not what it does afterwards.
Nothing specific on file for SkQ1 Plastoquinone. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What SkQ1 Plastoquinone actually does.
SkQ1 is a conjugate: a plastoquinone head group joined by a decyl linker to a triphenylphosphonium cation. The two halves do different jobs, one targets and one acts.
Lipophilic cations such as triphenylphosphonium accumulate inside mitochondria because the inner membrane carries a large negative electrical potential on the matrix side. The accumulation follows the Nernst relationship, which is why concentration inside the organelle can be many times that outside without any transporter being involved.
Plastoquinone is the electron carrier of the photosynthetic electron transport chain in chloroplasts, structurally analogous to ubiquinone in mitochondria. Both cycle between an oxidised quinone and a reduced quinol by way of a semiquinone intermediate.
The quinol form donates hydrogen atoms to lipid peroxyl radicals, interrupting the chain reaction of lipid peroxidation in a membrane. Cardiolipin, which is specific to the inner mitochondrial membrane and rich in unsaturated acyl chains, is a principal target of that peroxidation.
Where SkQ1 Plastoquinone comes from.
This is a designed molecule, not something extracted from a plant and bottled. Chemists take a quinone, the kind of electron-carrying unit plants use in photosynthesis, and bolt it onto a positively charged chemical tag through a ten-carbon chain. The positive tag is the point: mitochondria carry a strong negative charge inside, so the whole molecule is pulled in and concentrates there. The finished eye drop contains a tiny fraction of a percent of it.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The quinone portion is prepared synthetically or derived from plant chloroplast material; triphenylphosphine is a bulk industrial reagent.
A decyl chain with a leaving group at one end is coupled to the quinone, setting the distance between the charged head and the redox head. That distance is a designed parameter and is what distinguishes the family members from one another.
Triphenylphosphine displaces the leaving group on the alkyl chain to form the quaternary phosphonium cation, giving the permanent positive charge that drives mitochondrial accumulation. The halide released becomes the counter-ion.
Column chromatography separates the product from unreacted phosphine, from linker byproducts and from over-alkylated species. Quinones are also oxygen and light sensitive during handling.
Material is assayed for the phosphonium conjugate and characterised for the ratio of quinone to quinol, since the two states behave differently.
Finished ophthalmic concentrations are in the range of thousandths of a percent, so the dilution step from raw material to product is very large.
Specific reaction conditions, the exact source of the quinone head group, and the finished excipient system are proprietary to the manufacturer and are not published in a form that can be verified here.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.